Dr Jiri Pavlu is a Consultant Haematologist at Hammersmith Hospital and Honorary Clinical Senior Lecturer at Imperial College London. He is the clinical lead for acute leukaemia and myelodysplastic syndromes at Imperial College Healthcare.
He is active in clinical research and uses the latest drugs and treatments to offer highly personalised care. His scientific research focuses acute leukaemia and on improvements in the safety and patient outcomes of transplantation. He is an active member of the acute leukaemia working parties in both the National Cancer Research Institute and the European Bone Marrow Transplantation Society (EBMT). He is also an accredited transplantation quality assurance inspector (Joint Accreditation Committee – International Society for Cellular Therapy & EBMT).
et al., 2022, Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies, Nature Communications, Vol:13, ISSN:2041-1723, Pages:1-6
et al., 2022, Comparison of Outcomes after Unrelated Double-Unit Cord Blood and Haploidentical Peripheral Blood Stem Cell Transplantation in Adults with Acute Myelogenous Leukemia: A Study on Behalf of Eurocord and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, Transplantation and Cellular Therapy, Vol:28, ISSN:2666-6375
et al., 2022, Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT, Bone Marrow Transplantation, Vol:57, ISSN:0268-3369, Pages:1421-1427
et al., 2022, Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT, Bone Marrow Transplantation, Vol:57, ISSN:0268-3369, Pages:562-571
et al., 2022, Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia Working Party of the EBMT, Bone Marrow Transplantation, Vol:57, ISSN:0268-3369, Pages:399-406